-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Protalix BioTherapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2021 to Q3 2025.
- Protalix BioTherapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $59K, a 86.7% decline year-over-year.
- Protalix BioTherapeutics, Inc. Deferred Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $177K.
- Protalix BioTherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was $236K.
- Protalix BioTherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$3.09M.
- Protalix BioTherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $0.000.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)